drugset / Trial / NCT00613093
Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
Phase 2
Completed
67 enrolled
Duke University
Keryx / AOI Pharmaceuticals, Inc. · collabNational Institutes of Health (NIH) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Objectives: To define role of O6-Benzylguanine (BG) in restoring Temodar (temozolomide) sensitivity in patients with Temodar-resistant malignant glioma. To further define toxicity of combo therapy using Temodar + BG.
Timeline
- Start
- 2002-10
- Primary completion
- 2006-03
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | O6-benzylguanine | Small molecule | 30 mg/m2 | Intravenous |
| Comparator | Temozolomide | Small molecule | 472 mg/m2 | Oral |